抗ウイルス薬市場：薬剤タイプ、治療薬、最終用途別-2025-2030年の世界予測

抗ウイルス薬市場は、2023年に562億2,000万米ドルと評価され、2024年には598億4,000万米ドルに達すると予測され、CAGR 6.54％で成長し、2030年には876億1,000万米ドルに達すると予測されています。

抗ウイルス薬は、ウイルス感染の発生と拡大を抑制するために設計された医薬品です。その範囲は、HIV、肝炎、インフルエンザ、その他の伝染性ウイルス性疾患などの治療など、さまざまな用途に及ぶ。抗ウイルス薬の必要性は、アウトブレイクを制御・予防し、影響を受けやすい集団を保護し、公衆衛生の安全を確保する必要性から生じる。COVID-19やその他の新たなウイルスの脅威を背景に、効果的な抗ウイルス薬の需要が急増し、ヘルスケアにおける重要な役割が浮き彫りになっています。最終用途の範囲には、病院、診療所、研究所、在宅ケアの現場が含まれ、そこでは治療と予防の両方の目的で使用されます。

市場成長を促進する主な要因としては、進行中の研究と技術の進歩、ウイルス感染に対する意識の高まり、政府および民間セクターの投資の増加などが挙げられます。強力なパイプライン医薬品と新型ウイルス株の頻繁な出現は、市場拡大の潜在的機会をもたらします。企業は医薬品開発プロセスを加速させ、ウイルス動態の急速な変化に対応することで、これらを活用することができます。しかし、市場は高コスト、規制上の課題、ウイルス耐性の可能性といった限界に直面しており、抗ウイルス治療の普及とアクセシビリティの妨げとなっています。

イノベーションの機会は、個々の患者のニーズに合わせて薬剤を調整する個別化医療や、複数のウイルスを同時に標的とすることができる広域スペクトル抗ウイルス薬の開発にあります。さらに、創薬に人工知能や機械学習を活用することで、効果的な化合物の同定を加速できる可能性があります。抗ウイルス薬市場は、継続的な研究開発努力と急速な技術進歩を特徴とするダイナミックな市場です。企業は、変化する規制基準や新たな健康上の脅威に適応するために機敏性を維持しなければならないです。革新的なソリューションと戦略的提携に投資することで、企業は効果的な抗ウイルス療法に対する差し迫ったニーズを満たしながら成長を促進することができます。

市場力学：急速に進化する抗ウイルス薬市場の主要市場インサイトを公開

抗ウイルス薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • HIV、肝炎、インフルエンザなどのウイルス性疾患の増加
  • 抗ウイルス薬の開発における政府および民間部門の支出の増加
  • 顧客の認識を高めるための抗ウイルスプログラムおよびキャンペーンの増加
• 市場抑制要因
  • 抗ウイルス薬の治療費の高騰と特許失効の懸念
• 市場機会
  • 多くのウイルス感染症や疾患に対するワクチン製造の研究開発
  • HIVワクチン開発のための広範な処方
• 市場の課題
  • ホメオパシーなどの代替療法の普及

ポーターのファイブフォース：抗ウイルス薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗ウイルス薬市場における外部からの影響の把握

外部マクロ環境要因は、抗ウイルス薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗ウイルス薬市場における競合情勢の把握

抗ウイルス薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗ウイルス薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗ウイルス薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗ウイルス薬市場における成功への道筋を描く

抗ウイルス薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • HIV、肝炎、インフルエンザなどのウイルス性疾患の発生増加
    • 抗ウイルス薬の開発における政府および民間部門の支出の増加
    • 顧客の認知度を高めるためのウイルス対策プログラムやキャンペーンの増加
  • 抑制要因
    • 抗ウイルス薬治療の高額な費用と特許切れの懸念
  • 機会
    • 多数のウイルス感染症および疾患に対するワクチン製造の研究開発
    • HIVワクチン開発のための広範な処方
  • 課題
    • ホメオパシーなどの代替療法の普及
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 抗ウイルス薬市場薬の種類別

• ブランド医薬品
• ジェネリック医薬品

第7章 抗ウイルス薬市場セラピューティクス

• 後天性免疫不全症候群の治療薬
• 肝炎（B型およびC型）治療薬
• ヘルペス治療薬
• インフルエンザ治療薬
• 肺炎

第8章 抗ウイルス薬市場：最終用途別

• 外来手術センター
• クリニック
• 病院

第9章 南北アメリカの抗ウイルス薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の抗ウイルス薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの抗ウイルス薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abacus Bioscience Inc.
• Abbott Laboratories
• AbbVie Inc.
• Antiva Biosciences, Inc.
• AstraZeneca PLC
• Aurobindo Pharma
• Bristol-Myers Squibb Company
• Chimerix Inc.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• ENYO Pharma SA
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG

LIST OF FIGURES

• FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIVIRAL DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIVIRAL DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ACQUIRED IMMUNODEFICIENCY SYNDROME THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 147. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Antiviral Drugs Market was valued at USD 56.22 billion in 2023, expected to reach USD 59.84 billion in 2024, and is projected to grow at a CAGR of 6.54%, to USD 87.61 billion by 2030.

Antiviral drugs are pharmaceuticals designed to inhibit the development and spread of viral infections. Their scope encompasses several applications, including treating conditions like HIV, hepatitis, influenza, and other contagious viral diseases. The necessity for antiviral drugs arises from the need to control and prevent outbreaks, protect susceptible populations, and ensure public health safety. In the context of COVID-19 and other emerging viral threats, the demand for effective antiviral medications has surged, underscoring their critical role in healthcare. The end-use scope includes hospitals, clinics, research laboratories, and home care settings, where antiviral drugs serve both therapeutic and preventive purposes.

Key factors driving the market growth include ongoing research and technological advancements, rising awareness about viral infections, and increasing government and private sector investments. Robust pipeline drugs and the frequent emergence of new viral strains present potential opportunities for market expansion. Companies can capitalize on these by accelerating drug development processes and adapting to rapid changes in viral dynamics. However, the market faces limitations such as high costs, regulatory challenges, and the potential for viral resistance, which can impede widespread adoption and accessibility of antiviral treatments.

Innovation opportunities lie in personalized medicine, where drugs are tailored to individual patient needs, and in developing broad-spectrum antivirals that can target multiple viruses simultaneously. Additionally, leveraging artificial intelligence and machine learning for drug discovery could accelerate the identification of effective compounds. The antiviral drug market is dynamic, characterized by continuous R&D endeavors and rapid technological advancements. Companies must maintain agility to adapt to changing regulatory standards and emerging health threats. By investing in innovative solutions and strategic collaborations, businesses can drive growth while meeting the pressing need for effective antiviral therapies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiviral Drugs Market

The Antiviral Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
  • Rising government and private sector expenditure in the development of antiviral drugs
  • Growing number of antiviral programs and campaigns to increase customer awareness
• Market Restraints
  • High cost of antiviral drug treatment and concerns of patent expiration
• Market Opportunities
  • Research and development in the production of vaccines for numerous viral infections and diseases
  • Extensive formulations to develop HIV vaccines
• Market Challenges
  • Prevalence of alternative therapy such as homeopathy

Porter's Five Forces: A Strategic Tool for Navigating the Antiviral Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiviral Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiviral Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiviral Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiviral Drugs Market

A detailed market share analysis in the Antiviral Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiviral Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiviral Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiviral Drugs Market

A strategic analysis of the Antiviral Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Branded Drugs and Generic Drugs.
• Based on Therapeutics, market is studied across Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia.
• Based on End Use, market is studied across Ambulatory Surgical Centres, Clinics, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
    • 5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
    • 5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
  • 5.1.3. Opportunities
    • 5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
    • 5.1.3.2. Extensive formulations to develop HIV vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Prevalence of alternative therapy such as homeopathy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antiviral Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Branded Drugs
• 6.3. Generic Drugs

7. Antiviral Drugs Market, by Therapeutics

• 7.1. Introduction
• 7.2. Acquired Immunodeficiency Syndrome Therapeutics
• 7.3. Hepatitis (B & C) Therapeutics
• 7.4. Herpes Therapeutics
• 7.5. Influenza Therapeutics
• 7.6. Pneumonia

8. Antiviral Drugs Market, by End Use

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centres
• 8.3. Clinics
• 8.4. Hospitals

9. Americas Antiviral Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Antiviral Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abacus Bioscience Inc.
• 2. Abbott Laboratories
• 3. AbbVie Inc.
• 4. Antiva Biosciences, Inc.
• 5. AstraZeneca PLC
• 6. Aurobindo Pharma
• 7. Bristol-Myers Squibb Company
• 8. Chimerix Inc.
• 9. Cipla Limited
• 10. Dr. Reddy's Laboratories Ltd.
• 11. ENYO Pharma SA
• 12. F. Hoffmann-La Roche AG
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline PLC
• 15. Johnson & Johnson
• 16. Merck & Co., Inc.
• 17. Novartis AG